In a 12-to-1 vote, the FDA’s Pulmonary-Allergy Drug Advisory Committee voted against approving gefapixant 45 mg tablets to treat adults with refractory or unexplained chronic cough.The FDA is ...

A prescription for an opioid-containing cough suppressant was found in more adults with chronic vs. non-chronic cough, according to results published in Therapeutic Advances in Respiratory Disease ...

The NDA submission included data from two pivotal phase 3 trials, COUGH-1 (ClinicalTrials.gov Identifier: NCT03449134) and COUGH-2 (ClinicalTrials.gov Identifier: NCT03449147), as well as two ...

Refractory chronic cough represents a significant unmet need with no FDA-approved treatment options and $11B total addressable global market First-in-human Phase 1/1b single/multiple dose study in ...

For instance, in a 2024 review of chronic cough in adults, Peters et al. list asthma, gastroesophageal reflux, upper airway cough syndrome, and neuropathic cough as potential causes of cough.

Merck’s candidate to treat chronic cough didn’t show substantial evidence of effectiveness, according to the Food and Drug Administration. The Rahway, N.J.-based pharmaceutical company said ...

Chronic cough is the primary symptom of two other conditions, although these can be more challenging to diagnose: cough-variant asthma and eosinophilic bronchitis. Both conditions inflame the airways.

How can a long-standing cough that does not produce phlegm, and stops as soon as you fall asleep, be cured by watching a video?